Intercept Pharmaceuticals reported that its next-generation FXR agonist, INT-787, failed to show clear potential in a Phase 2 study, marking another setback for the Italian-owned liver-inflammation specialist. In the trial population with severe alcohol-associated hepatitis, the company said the asset showed “no clear evidence of potential.” The update adds to risk around FXR-centric programs in inflammatory liver disease, and it also signals a need for pipeline readouts that can re-earn confidence with regulators and investors. Intercept has previously been advancing multiple hepatic targets, but this result suggests INT-787 did not provide a viable path forward in its tested setting. For stakeholders, the key near-term issue will be what the company prioritizes next after a Phase 2 miss, including whether it shifts resources to other mechanisms or patient segments.